Moxifloxacin-induced drug hypersensitivity syndrome with features of toxic epidermal necrolysis

Journal of Drugs in Dermatology

Volumn 8, Issue 11, 2009, Pages 1031-1033

  Weaver, Chad H ^a   Huddleston, Hannah M ^a   Kingsley, Melanie M ^a   Wolverton, Stephen E ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; DIPHENHYDRAMINE; METHYLPREDNISOLONE; MOXIFLOXACIN; PREDNISONE; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CASE REPORT; CERVICAL LYMPHADENOPATHY; DRESS SYNDROME; DRUG ERUPTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MALE; PUNCH BIOPSY; SINUSITIS; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS; ASIAN; DRUG HYPERSENSITIVITY;

ADULT; ANTI-INFECTIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; AZA COMPOUNDS; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; MALE; QUINOLINES;

EID: 79957587093     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chave T, Mortimer N, Sladden M, et al. Toxic epidermal necrolysis: current evidence, practical management, and future directions. Br J Dermatol. 2005;153(2):241-253. (Pubitemid 41228420)
2. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: A prospective clinical study. Intensive Care Med. 1997;23(12):1237-1244. (Pubitemid 28017789)
3. Chosidow O, Delchier JC, Chaumette MT, et al. Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet. 1991;337(8746):928.
4. Wolf R, Orion E, Batsheva M, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;25:171-181. (Pubitemid 40410720)
5. Paquet P, Nikkels A, Arreses JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 2004;130(5):605-608.
6. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-493. (Pubitemid 28483679)
7. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: What is the pathogenesis? Arch Dermatol. 2001;137(3):357-364. (Pubitemid 32240793)
8. Wolkenstein P, Revuz J. Drug-induced severe skin reactions-Incidence, management and prevention. Drug Safety. 1995;13(1):56-68.
9. Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system. Chem Res Toxicol. 1999;12(5):387-395. (Pubitemid 29352401)
10. Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol. 1998;134(9):1108-1112. (Pubitemid 28432325)
11. Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137(3):301-304. (Pubitemid 32240782)
12. Conilleau V, Dompmartin A, Verneuil L, et al. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis. 1999;41(3):141-144. (Pubitemid 29405593)
13. Bayer HealthCare. (2008). Avelox [package insert]: Product monograph part 3. http://www.bayerhealth.com/BayerHC/ display.cfm?Object-ID=272&Article- ID=56&expandMenu- ID=53&prevSubItem=5-52. Acessed June 13, 2008
14. Miravitlles M, Llor C. Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primarycare setting. Clin Drug Invest. 2007;27(2):95-104. (Pubitemid 46143284)
15. Nori S, Nebesio C, Brashear R, Travers J. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol. 2004;140(12):1537-1538. (Pubitemid 39627455)
16. Lee H, Pang S, Thamotharampillai T. Allopurinol-induced Stevens- Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2008;59(2):352-353. (Pubitemid 351970107)
17. Huang L, Liao W, Chiou C, et al. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine- induced Stevens-Johnson syndrome. J Formos Med Assoc. 2007;106(12):1032-1037.
18. Valeyrie-Allanore L, Sassolas B, Roujeau J. Drug-induced skin, nail and hair disorders. Drug Safety. 2007;30(11):1011-1030. (Pubitemid 350036602)